Cocaine-and amphetamine-regulated transcript-derived peptides (CARTp) and corticotropin-releasing factor (CRF) alter feeding and gastrointestinal function following central administration and the gastric inhibitory effects are mediated through corticotropin-releasing factor. We hypothesized that dorsal hindbrain effects of CARTp on gastric emptying are mediated by the vagus nerve, and that the dorsal vagal complex (DVC) is a site of action for the gastric inhibitory effects of both CARTp and CRF. Rats were equipped with chronic intragastric fistulas and guide cannulas aimed at the fourth ventricle or the DVC. Fourth i.c.v. CARTpinduced suppression of 12 ml glucose (12.5%) gastric emptying during fill was blocked by subdiaphragmatic vagotomy. To establish whether the dorsal vagal complex may be a site of action for CARTp and/or CRF, intraparenchymal microinjections (0.25 µl) of CARTp (0.1 and 0.5 µg), and CRF (5 pmol and 10 pmol) were administered into the DVC. Each dose, previously shown to be ineffective after 4 th i.c.v. administration, suppressed gastric emptying during gastric fill vs. vehicle, but neither peptide changed gastric secretion volume or gastric acidity. The results indicate that the DVC is a target site for CRF and CARTp to inhibit gastric emptying, and that the vagus mediates dorsal hindbrain effects of CARTp on gastric motor function.
INTRODUCTION
CART and CART-derived peptides (CARTp) are widely distributed in the brain, and present in structures of the brainstem that are involved in integration of signals from the gastrointestinal tract, including the nucleus of the solitary tract (NTS) (4, 12, 2) . CARTp is also found in the vagus nerve (2) and CART and CARTp are present in the nodose ganglion (2) . upon vagal neurotransmission. Although local injection of CRF into the dorsal vagal complex (DVC) reduces TRH-induced gastric contractility (7) , it remains to be established whether the DVC is a target site for CRF to suppress gastric emptying and/or gastric acid secretion. Receptors for CRF are present in the DVC (19) and local injection of the CRF agonist urocortin into the DVC has been shown to suppress food intake in the rat (6) . Thus, the DVC is one likely site of action for the gastric inhibitory actions of both CARTp and CRF.
In the present study, the possibility that the vagus nerve mediates dorsal hindbrain CARTp-induced suppression of gastric emptying is examined. Further, the hypothesis that CARTp and CRF each act within the DVC to cause suppression of gastric emptying and gastric acid secretion is assessed by microinjection of each peptide, at doses shown to be ineffective after 4 th i.c.v. delivery, into the DVC of freely moving rats.
MATERIALS AND METHODS
Male Sprague Dawley rats (Charles River laboratories, Wilmington MA), weighing 300 g (experiment 1) or 450 g (experiment 2) at the time of surgery, were used. Rats were housed singly under conditions of controlled temperature, humidity and illumination (lights on 7 am-7pm) and drinking water was provided ad libitum. In experiment 1, the animals were maintained on a liquid diet (Ensure) provided ad libitum as previously described (18) . In experiment 2, the animals had free access to standard rat chow (Prolab RMH 1000). The experimental protocols were in accordance with NIH guidelines and were approved by the Animal Care and Use Committee at Johns Hopkins University School of Medicine.
Surgery
For surgical procedures, the rats were anesthetized with a 4:3 mixture of Ketamine (100 mg/ml; Phoenix Pharmaceutical, St Joseph, MO) and Xylazine (20 mg/ml, Phoenix Pharmaceutical, St Joseph, MO), injected intramuscularly (i.m.). The dose was 1 ml /kg body weight (bw). Chronic gastric fistulas were implanted into the ventral forestomach as previously described (9, 20) . For the first experiment, subdiaphragmatic vagotomies or sham surgeries were carried out in combination with gastric fistula implantation. The vagal trunks and their major branches were identified on the esophagus. The vagal trunks were cut proximal to the bifurcations of the hepatic and coeliac branches. In order to prevent any potential nerve regeneration, all vagal branches were cleared from the lower end of the esophagus and cut a second time, 10 mm distal to the proximal section of the vagal trunks, and the nerve tissue intersections were removed. Finally, the esophagus was carefully inspected under a dissecting micropscope to ensure that no intact vagal nerve fibers remained. Sham surgeries were performed in a similar way, however, no nerve cuts were performed. The wound was closed and the animals were allowed 9 days of recovery before implantation of fourth intracerebroventricular (4 th i.c.v.), or DVC, guide cannulas.
The procedure for stereotaxic implantation of chronic, 27 G guide cannulas, aimed at the fourth ventricle or the DVC, was performed as previously described for 4 th i.c.v. and N. raphe injections (20, 8) . The 10 mm guide reached, but did not penetrate, the dura mater. For 4 th i.c.v. placements, the coordinates were 2.6 mm anterior to the occipital crest in the midline. For the intraparenchymal placements, the guide coordinates were 1.60 mm anterior to the occipital crest, and 0.60 mm lateral to the midsagittal line, aiming at the right DVC. The animals were allowed another 6-7 days of recovery before the beginning of habituation training sessions.
Procedure
The experiments were carried out every third day to avoid possible carry-over effects of the peptides. The animals experienced each set of conditions once, in a balanced, crossover design. The testing was carried out between 2 and 5:30 pm, with each animal tested at approximately the same time point each day. The animals were habituated to the experimental procedure during 4 once-daily training sessions, in which they underwent the entire testing protocol, but received no central injections. The gastric fistulas were opened 60 min before testing, and intragastric contents were carefully evacuated with water per lavage, and the animals were subsequently placed in Plexiglas test cages with wire mesh floors. Just prior to testing, the fistulas were again opened and a silicone tube connected to a syringe mounted on a Harvard Pump 22 (Harvard Instruments, Natick, MA) was attached. An intragastric infusion (1.0 ml/min) of 12.5% glucose was delivered during 12 min, and immediately after infusion offset, the silicone tube was clamped and cut closely to the opening of the fistula. The remaining intragastric glucose solute was rapidly aspirated, either at the termination of the infusion, or 30 min later, and the volume of the collected sample was measured. The stomachs were then rinsed with 5.0 ml distilled water, in order to collect any solute still remaining intragastrically. The animals were gently restrained by hand, the injection needle was inserted through the guide and into the brainstem, and drug or vehicle (0.25 µl/min) was infused over 60 s. The accuracy of the volumes delivered with this system, commonly used for microdialysis, is + 1% and the reproducibility is + 0.1% at this Hamilton syringe size and flow rate, as determined by the manufacturer (Harvard Apparatus). After drug delivery, the injector was left in place for 30 seconds to reduce any risk of backflush. The injection needle was finally removed and a new obturator was inserted in the guide. After the last experimental testing session, the animals were anesthetized and 0.25 µl of India ink was injected using the same Harvard pump 11 injection system. The animals were sacrificed by decapitation, the brains were removed, frozen and sectioned. After staining with Cresyl Violet, microscopic inspection of the sections was performed and the location of each ink trace was recorded on a brainstem atlas sheet. Presence of India ink was found in the DMX and/or overlying ventral NTS (Fig. 2) . In one animal, the ink trace extended more ventrally into the brainstem as well (not shown in the figure). The data collected from this rat was excluded from the study.
Drugs
Synthetic CART (55-102) peptide (rat) (American Peptide Company Inc., Sunnyvale, CA) and CRF rat, human (Sigma Aldrich) were dissolved in saline, aliquoted and frozen (-20 o C). Fresh aliquots were thawed on each experimental day before injections, and any excess was discarded. Pentagastrin (Sigma-Aldrich) was dissolved in saline.
Experimental design

Experiment 1.
This experiment was designed to establish whether the vagus nerve participates in mediating the effects of 4 th i.c.v. CARTp on gastric emptying during and after fill. In addition, the effects of 4 th i.c.v. CARTp on the two phases of gastric emptying controls, during and after gastric fill (9) , was evaluated. Fifteen minutes prior to testing, vagotomized and sham-operated rats received a 4 th i.c.v. injection of 1.0 µg (190 pmol) CARTp, a dose previously shown effective to suppress emptying after 4 th i.c.v. delivery (23) . At time= 0, the animals were given a 12 min intragastric infusion of glucose (1.0 ml/min). Gastric samples were either collected immediately after the glucose infusion to reflect gastric emptying during gastric fill, or 30 minutes later, to reflect emptying in the post-fill period. As a control experiment for the sensitivity of the gastric acid secretion paradigm, pentagastrin (10 µg/kg) or saline as a control was injected (1ml/kg, i.p.) 15 min prior to intragastric infusion onset. A 12 ml glucose (12.5%) infusion was administered at 1.0 ml/min.
The stomach was evacuated at infusion offset, and the gastric contents were analyzed for gastric acidity as described above.
Statistical analysis
Results from experiment 1 were analyzed with a three-way mixed design ANOVA For experiment 2, the effects of CRF and CARTp were analyzed separately, with repeated measures ANOVA, using the same control condition. Post hoc comparisons were performed with Dunnett's test. We considered p<0.05 as significant.
Results from experiment 3 was analyzed using a paired, two-tailed Student's t-test.
RESULTS
Experiment 1. Fig. 1 shows the effect of CARTp on gastric emptying during and following gastric fill in intact (n=7) and vagotomized (n=9) rats. The ANOVA revealed main effects of 4 th i.c.v. CARTp (F [1, 14] =102.846, p<0.001), sample latency (12 and 42 min after infusion onset) (F [1, 14] =23.001, p<0.001) and of vagotomy (F [1, 14] =4.878, p<0.05). There were no significant two-way interactions (vagotomy x sample latency; vagotomy x CARTp treatment;
sample latency x CARTp treatment) but there was a significant three-way interaction (vagotomy In experiment 3, students's t-test showed that gastric acidity was increased from 2.63 (+0.36) µeq/ml to 7.96 (+1.91) µeq/ml in response to pentagastrin (Fig. 5 ).
DISCUSSION
Although the receptors for CARTp are yet to be described, the distribution of CARTp in vagal structures such as the NTS, nodose ganglion and area postrema suggests roles for both the DVC and the vagus nerve in mediating the ability of CARTp to modulate gastrointestinal physiology. Consistent with this view, a previous study by Okumura et al. (17) demonstrated a role for the vagus to mediate central nervous CARTp inhibition of gastric acid secretion. Our present results extend that finding to demonstrate that the vagus also mediates CARTp-induced suppression of gastric emptying during gastric fill, and that the DVC may be a target for CARTp as well as CRF -induced effects on gastric emptying.
Our first experiment provides an important characterization of CARTp-induced inhibition of gastric emptying. First, we showed that the ability of 4 th i.c.v. CARTp to suppress gastric emptying was limited to the during-fill period. CARTp produced a significant suppression of emptying during gastric fill ( fig. 1) (23) but the effect of CARTp was eliminated in the postfill period. In fact, postprandial emptying was relatively increased after CARTp treatment such that at the 30 min post-fill time point, emptying was the same with and without CARTp administration. The mechanism underlying this rebound increase in gastric emptying following CARTp-induced, during-fill gastric emptying suppressions, is not fully clear. The controls of emptying during and following the period of gastric fill differ. Post-fill emptying depends upon caloric, post-pyloric feedback (15) . The CARTp-induced reduction in within-fill gastric emptying produces less of a caloric, postpyloric signal, which, in turn, may account for the post-fill acceleration in gastric emptying following CARTp administration. Such a rebound acceleration following a during-fill gastric emptying suppression is similar to what has been previously demonstrated for the somatostatin agonist octreotide (21) . In response to s.c. octreotide administration, which potently suppresses emptying during gastric fill, there is a rapid rebound increase in the emptying rate that occurs immediately after the cessation of gastric fill regardless of the duration of the intragastric infusion, so that cumulative emptying, which includes the during-and post-fill periods, is unaffected (21) . That CARTp and octreotide should produce similar emptying dynamics is not surprising. Previous work has suggested that CARTp-induced gastric emptying inhibition is CRF dependent (23) and that CRF's gastric inhibitory actions are mediated through somatostatin (20, 21, 22) . Thus, somatostatin may be an additional downstream mediator of the gastric inhibitory actions of CARTp.
Results from the second experiment demonstrate that the DVC is a potential site of action for 4 th i.c.v. CARTp. Direct DVC injections of CARTp at doses that do not affect gastric emptying when administered into the 4 th ventricle, significantly suppressed during fill gastric emptying. This is consistent with prior reports demonstrating the presence of CARTp in the vagus nerve (12) and in the nodose ganglion (2, 12) , the NTS, as well as the area postrema (4, 12) .
This finding is also consistent with the results of experiment 1 demonstrating the disruption of hindbrain CARTp effects on gastric emptying by vagotomy ( Fig. 1) . Recently, we showed that the controls for 4 th i.c.v. CARTp-induced suppression of gastric emptying, but not of sucrose ingestion, are separable, since the former, but not the latter is blocked by pretreatment with a CRF antagonist (23) . Given a recent report by Zheng et al. (27) , where 4 th i.c.v. CARTp was shown to suppress sucrose intake, but microinjection of CARTp into the DVC was without effect, our results from experiment 2 showing significant effects on gastric emptying suppression after local DVC injection, suggest that the vagally associated CARTp (4,12,2) is involved in strictly controlling gastrointestinal functions.
The DMX/NTS complex is the final common path for vagal transmission. Results from experiment 2, showing a significant suppression of gastric emptying after CARTp microinjection into the DVC, also demonstrated a similar action for CRF. Earlier studies on central actions of CRF and CARTp in the rat showed that both peptides act via vagal pathways to affect gastric acid secretion (24, 5, 17) and centrally acting CRF was shown to inhibit gastric emptying in part via a vagal mechanism (2, 25) . Further, CRF (20) and CARTp (23) cause suppression of gastric emptying when delivered 4 th i.c.v., suggesting an action on receptors within the dorsal hindbrain. The present data establish that the DVC may not only relay the effects of CARTp or CRF on gastric emptying suppression, elicited in other hindbrain areas, but importantly, that the DVC may be a site of action for CARTp and for CRF to control gastric emptying. The finding that CARTp and CRF act in the DVC to inhibit gastric emptying does not, of course, exclude other brainstem substrates as additional candidate target sites after intraventricular or intracisternal delivery. Other areas in the hindbrain, that express receptors for these peptides and that project to the DVC, may be simultaneously targeted after intraventricular injection of CARTp and/or CRF.
In the present study, we did not detect any changes in gastric acidity or volume of gastric secretions in the during-fill period in response to either CARTp ( Fig. 3B and 3C) or CRF ( fig. 4B and 4C ) administered into the DVC. These data are similar to our previous findings following 4 th i.c.v. administration of CARTp (23) and CRF (20) . The previous observation that the rate of gastric secretion is higher during, than after, gastric fill (9) in the similar paradigm, would suggest that any diminution of secretion would have been easy to detect. This lack of effect on secretion volume and gastric acidity contrasts to findings from previous studies of the intraventricular effects of CARTp (17) and CRF (14, 24, 5) where gastric acid secretion and secretion volume, were significantly reduced. An explanation for the discrepancies may be that agents delivered i.c. or i.c.v. are more likely to access and target multiple putative receptor substrates as well, than after local DVC microinfusion. This would suggest that whereas the DVC appears to be a target for CRF and CARTp to suppress gastric emptying, it may not be a direct site of action for these peptides to cause inhibition of gastric acid secretion or changes in gastric Most previous studies on CRF-induced inhibition of gastric acid secretion have typically been performed in pylorus-ligated rats where samples were collected after 1-2 hrs (24, 14) . To validate the sensitivity of our method, we confirmed in experiment 3 that changes in acidity are detected over a shorter period (12 min), as indicated by the increase in acidity in response to a typical dose of pentagastrin (Fig. 5 ). This is consistent with previous studies on histamine effects in the guineapig, in a similar testing paradigm (1) . In this context, it should be emphasized that our testing paradigm assesses gastric emptying of glucose and gastric acid secretion during gastric fill in a manner that resembles the short term food intake situation, i.e., glucose is infused intragastrically in a volume and rate that is similar to what rats would normally ingest from a drinking spout (10) . Importantly, basal gastric emptying during fill after intragastric infusion of glucose does not differ from emptying rates that are observed after ingestion of the same stimulus (9, 10, 11) . Our finding that no suppression of gastric secretion volume or acid secretion by either CRF or CARTp injected into the DVC could be detected during gastric fill, may therefore infer that the acid secretion suppression observed over 4 h by Okumura et al. (17) , may not be of physiological relevance during ongoing food ingestion.
In summary, dorsal hindbrain CARTp suppresses gastric emptying during gastric fill, but not after gastric fill, via a vagal pathway. In addition, CARTp and CRF each act in the DVC to inhibit gastric emptying, without changing gastric acid secretion or gastric secretion volume. 
